Liver Cancer Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Liver Cancer Therapeutics Market is segmented by type (hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma and others), therapy, and geography.

Market Snapshot

Study Period:

2018 - 2026

Base Year:


Fastest Growing Market:

Asia Pacific

Largest Market:

North America


8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The major factors for the growth of the liver cancer therapeutics market include the rising prevalence of liver cancer, increasing R&D investments for the development of novel therapies, and government initiatives to increase cancer awareness. The change in the current lifestyle has led to the exposure of a large amount of the population to certain risk factors that contribute to liver cancer. The risk factors include hepatitis (caused by either the hepatitis B or hepatitis C virus), type 2 diabetes, metabolic disorders, and excess body weight, alcohol consumption, and tobacco smoking. Liver cancer risk increases substantially with the increase in one’s body mass index (BMI). More than half of the adult population in the United States falls under the category referred to as overweight. According to the American Cancer Society estimates, there would be around 42,810 new liver cancer cases in the United States in 2020. Moreover, the high demand for therapeutic drugs for liver cancer will create wide opportunities for the manufacturers to produce more drugs, and thereby, the market is expected to witness a high CAGR over the forecast period.

Scope of the Report

Liver cancer is cancer that begins in the liver cells. Cancer starts when cells in the body begin to grow out of control. This market is segmented by type, therapy, and geography.

By Type
Hepatocellular Carcinoma
Cholangio Carcinoma
By Therapy
Targeted Therapy
Radiation Therapy
North America
United States
United Kingdom
Rest of Europe
Asia Pacific
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Hepatocellular Carcinoma is the Segment by Type is expected to be the Fastest Growing Segment

Hepatocellular carcinoma (HCC) is the most common form of liver cancer, which mostly occurs in people suffering from chronic liver diseases, like cirrhosis. Hepatocellular carcinoma is one of the major causes leading to cancer-related deaths worldwide. It is observed that the Asian and African countries have higher incidence rates of hepatocellular carcinoma than the developed world, due to the disparity in the major risk factors causing hepatocellular carcinoma, such as hepatitis C virus (HCV) and hepatitis B virus (HBV) infection in those regions. As per the data published by the National Organization for Rare Diseases (NORD), there are approximately six new cases of HCC per every 100,000 people in the general population of the United States. With the increase in the incidence of hepatocellular carcinoma, there is expected to be a huge demand for the liver cancer therapeutics. Hence, the rising incidence of cancer and high unmet medical needs are the major factors that drive the market in the forecast period.

To understand key trends, Download Sample Report

North America is Expected to Dominate the Market Over the Forecast Period

North America is expected to dominate the market, due to the presence of better healthcare infrastructure and rising geriatric population. According to the estimates of the American Society of Clinical Oncology, there are 42,220 adults who are diagnosed with liver cancer in the United States in 2018, (of which there are 30,610 men and 11,610 women). Hence, the incidence of liver cancer in the United States is increasing This is leading to an increasing demand for liver cancer treatment, which, in turn, is driving the market in the forecast period.

To understand geography trends, Download Sample Report.

Competitive Landscape

The market studied is a consolidated market, owing to the presence of a few major market players. Market players are focusing on R&D to bring innovative treatments for the treatment of liver cancer. Some of the market players are F. Hoffmann-La Roche Ltd, Bayer AG, Bristol‑Myers Squibb Company, Celsion Corporation, Eisai Inc., Exelixis Inc, F. Hoffmann-La Roche Ltd, Merck & Co Inc. and Eli Lilly and Company.

You can also purchase parts of this report. Do you want to check out a section wise price list?

Table Of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Burden of Liver Cancer

      2. 4.2.2 Increasing R&D investments for the development of novel therapies

      3. 4.2.3 Government Initiatives to Increase the Cancer Awareness

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects associated with Certain Medications Coupled with High Cost of Cancer Therapies

      2. 4.3.2 Stringent Regulatory Scenario

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Type

      1. 5.1.1 Hepatocellular Carcinoma

      2. 5.1.2 Cholangio Carcinoma

      3. 5.1.3 Hepatoblastoma

      4. 5.1.4 Other

    2. 5.2 By Therapy

      1. 5.2.1 Targeted Therapy

      2. 5.2.2 Radiation Therapy

      3. 5.2.3 Immunotherapy

      4. 5.2.4 Chemotherapy

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. United Kingdom

        2. Germany

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 F. Hoffmann-La Roche Ltd

      2. 6.1.2 Bayer AG

      3. 6.1.3 Bristol-Myers Squibb Company

      4. 6.1.4 Celsion Corporation

      5. 6.1.5 Eisai Inc.

      6. 6.1.6 Exelixis, Inc

      7. 6.1.7 Eli Lilly and Company

      8. 6.1.8 Merck & Co., Inc.

  7. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Related Reports